2024

1. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

   Clinical Cancer Research, Vol. 30, Núm. 20, pp. 4609-4617

2. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

   Lung Cancer, Vol. 197

3. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

   Future Oncology, Vol. 20, Núm. 13, pp. 799-809

4. Access to melanoma drugs in Spain: a cross-sectional survey

   Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

5. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

   Clinical and Translational Oncology

6. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

   Molecular Cancer, Vol. 23, Núm. 1

7. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)

   International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945

8. Antibody-drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer

   International Journal of Gynecological Cancer

9. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

   Journal of Clinical Oncology

10. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

11. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

    Radiotherapy and Oncology, Vol. 198

12. Comparison of staging using [68Ga]Ga-PSMA-11 PET/CT and histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection

    Revista Espanola de Medicina Nuclear e Imagen Molecular

13. Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer

    Seminars in Oncology Nursing, Vol. 40, Núm. 1

14. Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines

    Reports of Practical Oncology and Radiotherapy, Vol. 29, Núm. 3, pp. 340-347

15. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

    Clinical Genitourinary Cancer, Vol. 22, Núm. 5

16. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138

17. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

    Advances in Therapy, Vol. 41, Núm. 11, pp. 4125-4139

18. First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies

    Clinical Genitourinary Cancer

19. GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR

    Radiotherapy and Oncology, Vol. 201

20. HRD testing for all advanced high-grade ovarian carcinoma in first line?

    ESMO Open